Gold prices edge lower; heading for weekly losses ahead of U.S.-Russia talks
Director Paul A. Friedman of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) sold 41,000 shares of common stock on August 11 and 12, 2025, for approximately $16.6 million. The sales were executed at prices ranging from $350.1911 to $359.81. The transactions occurred as MDGL shares trade near their 52-week high of $377.46, following a strong 10.46% gain last week. According to InvestingPro analysis, the stock appears slightly undervalued based on its Fair Value model.
The sales were executed under a Rule 10b5-1 trading plan adopted on March 14, 2025.
On the same dates, Friedman also exercised options to acquire a total of 46,808 shares of Madrigal Pharmaceuticals common stock at a price of $9.45 per share, for a total value of $442335.
Following these transactions, Friedman directly owns 201,230 shares of Madrigal Pharmaceuticals, Inc. common stock. He also indirectly owns 655,540 shares through SQN LLC. With MDGL’s current market capitalization of $8.35 billion and strong analyst consensus, these holdings represent significant insider commitment to the company.
In other recent news, Madrigal Pharmaceuticals reported strong second-quarter earnings, with Rezdiffra sales reaching $212.8 million, significantly surpassing both Goldman Sachs’ estimate of $150.9 million and the FactSet consensus of $159.4 million. This performance marks a 55% increase from the previous quarter, driven by robust patient demand and increased prescriber penetration. Jefferies has raised its price target for Madrigal Pharmaceuticals to $502, following the extension of a weight-based dosing patent for Rezdiffra, now protected until February 2045. Piper Sandler has reiterated its Overweight rating on Madrigal, expressing confidence in the launch progress of Rezdiffra for MASH. Additionally, Madrigal secured a $500 million credit facility with Blue Owl Capital to advance its MASH pipeline, including a $350 million initial term loan. The company also entered into an exclusive global license agreement with CSPC Pharmaceutical Group for SYH2086, a preclinical oral small molecule GLP-1 receptor agonist. This agreement involves an upfront payment of $120 million and potential milestone payments up to $2 billion, with the transaction expected to close in the fourth quarter of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.